<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7294848\results\search\testTrace\results.xml">
  <result pre="rapidly evolving pandemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2)" exact="infection" post="worldwide cost many lives. The angiotensin converting enzyme-2 (ACE-2)"/>
  <result pre="this perspective, we predominantly focus on the impact of SARS-CoV-2" exact="infection" post="on ACE2 and dysregulation of the protective effect of"/>
  <result pre="age of 50 years. Given the fact of a higher" exact="prevalence" post="of metabolic diseases, including obesity, hypertension, cardiovascular diseases and"/>
  <result pre="diabetes in the US population (Moore et al., 2017), this" exact="infection" post="may cause higher mortality. The virus gains entrance into"/>
  <result pre="receptor. How the known epidemiological and clinical manifestation of SARS-CoV-2" exact="infection" post="may be explained by perturbations of physiological functions of"/>
  <result pre="myocardial injury, renal failure, and increased mortality due to SARS-CoV-2" exact="infection" post="among the aging population and subjects with cardiovascular and"/>
  <result pre="and Ang II levels return to baseline 1 week after" exact="treatment" post="with ACE inhibitors (Mento and Wilkes, 1987). Furthermore, it"/>
  <result pre="However, pathological examination on autopsies have not investigated if SARS-CoV-2" exact="infection" post="leads to total destruction of ACE2 receptors on the"/>
  <result pre="Recent efforts have been put forward of drug repurposing by" exact="screening" post="of various available antiviral agents with the aim to"/>
  <result pre="to identify possible treatments. Among those, lopinavir, originally used for" exact="treatment" post="of human immunodeficiency virus, was identified to have potential"/>
  <result pre="randomized-controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2" exact="infection" post="showed no benefit of lopanavir (Cao et al., 2020)."/>
  <result pre="at micromolar concentration of remdesivir and chloroquine potentially blocked virus" exact="infection" post="(Wang M. et al., 2020). Current clinical trials are"/>
  <result pre="clinical trials are ongoing to assess the efficacy of remdesivir" exact="treatment" post="alone or in conjunction with chloroquine in SARS-CoV-2 infection."/>
  <result pre="a lack of significant efficacy of antimalarial drugs in the" exact="treatment" post="of SARS-CoV-2 infection (Magagnoli et al., 2020). Corticosteroids are"/>
  <result pre="significant efficacy of antimalarial drugs in the treatment of SARS-CoV-2" exact="infection" post="(Magagnoli et al., 2020). Corticosteroids are the most conventional"/>
  <result pre="RAS activation through the ACE2/(Ang1-7)/MAS pathway should be considered for" exact="treatment" post="of this disease. Furthermore, our clinical observation and published"/>
  <result pre="may not be a direct effect of the initial viral" exact="infection" post="but rather the hosts reaction to the loss of"/>
  <result pre="II is feasible and might be effective for the symptomatic" exact="treatment" post="of these patients. Concluding Remarks Based on the importance"/>
  <result pre="epithelial cells and lung injury? (2) What effect(s) does SARS-CoV-2" exact="infection" post="of lung epithelial cells/endothelial cells have on ACE2 expression"/>
  <result pre="on the binding of SARS-CoV-2 to the ACE2 receptor and/or" exact="infection" post="of lung epithelial cells? Regardless, these are questions of"/>
  <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of mice. J. Immunol.173, 4030â€&quot;4039. 10.4049/jimmunol.173.6.403015356152 GopallawaI.UhalB. D. (2014)."/>
  <result pre="ACE2-Ang-(1-7)-Mas axis in brain: a potential target for prevention and" exact="treatment" post="of ischemic stroke. Curr. Neuropharmacol.11, 209â€&quot;217. 10.2174/1570159X1131102000723997755 KatoH.HouJ.ChobanianA. V.BrecherP."/>
  <result pre="inhibition. Hypertension9:III42. 10.1161/01.HYP.9.6_Pt_2.III423036705 MooreJ. X.ChaudharyN.AkinyemijuT. (2017). Peer reviewed: metabolic syndrome" exact="prevalence" post="by race/ethnicity and sex in the United States, National"/>
 </snippets>
</snippetsTree>
